Niu Runyan, Liu Xuexue, Yang Xian, Du Xiao, Wang Siliang, Ma Xiaolong, Yin Shaoping, Shao Lihua, Zhang Jinping
Nanjing Medical Center for Clinical Pharmacy, Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210008, China.
Pharmaceutics. 2025 Jan 6;17(1):68. doi: 10.3390/pharmaceutics17010068.
Nanoparticle-based drug delivery systems hold great promise for improving the effectiveness of anti-tumor therapies. However, their clinical translation remains hindered by several significant challenges, including intricate preparation processes, limited drug loading capacity, and concerns regarding potential toxicity. In this context, pure drug-assembled nanosystems (PDANSs) have emerged as a promising alternative, attracting extensive research interest due to their simple preparation methods, high drug loading efficiency, and suitability for large-scale industrial production. This innovative approach presents new opportunities to enhance both the safety and therapeutic efficacy of cancer treatments. This review comprehensively explores recent progress in the application of PDANSs for cancer therapy. It begins by detailing the self-assembly mechanisms and fundamental principles underlying PDANS formation. The discussion then advances to strategies for assembling single pure drug nanoparticles, as well as the co-assembly of multiple drugs. Subsequently, the review addresses the therapeutic potential of PDANSs in combination treatment modalities, encompassing diagnostic and therapeutic applications. These include combinations of chemotherapeutic agents, phototherapeutic approaches, the integration of chemotherapy with phototherapy, and the synergistic use of immunotherapy with other treatment methods. Finally, the review highlights the potential of PDANSs in advancing tumor therapy and their prospects for clinical application, providing key insights for future research aimed at optimizing this technology and broadening its utility in cancer treatment.
基于纳米颗粒的药物递送系统在提高抗肿瘤治疗效果方面具有巨大潜力。然而，其临床转化仍受到若干重大挑战的阻碍，包括复杂的制备工艺、有限的载药能力以及对潜在毒性的担忧。在此背景下，纯药物组装纳米系统（PDANSs）作为一种有前景的替代方案应运而生，因其制备方法简单、载药效率高且适合大规模工业生产而吸引了广泛的研究兴趣。这种创新方法为提高癌症治疗的安全性和疗效带来了新机遇。本综述全面探讨了PDANSs在癌症治疗应用中的最新进展。首先详细阐述了PDANS形成的自组装机制和基本原理。接着讨论了单种纯药物纳米颗粒的组装策略以及多种药物的共组装。随后，综述阐述了PDANSs在联合治疗模式中的治疗潜力，包括诊断和治疗应用。这些包括化疗药物的联合、光疗方法、化疗与光疗的结合以及免疫疗法与其他治疗方法的协同使用。最后，综述强调了PDANSs在推进肿瘤治疗方面的潜力及其临床应用前景，为未来旨在优化该技术并拓宽其在癌症治疗中应用范围的研究提供了关键见解。
